ICG Leads $76 Million Series B Investment in Mediar Therapeutics

Reuters01-07

ICG Leads $76 Million Series B Investment in Mediar <a href="https://laohu8.com/S/LENZ">Therapeutics</a>

ICG plc, through its Life Sciences team, has co-led an oversubscribed $76 million Series B equity financing round for Mediar Therapeutics, Inc., a clinical-stage biotechnology company focused on first-in-class therapies for fibrotic diseases. The round was co-led with Amplitude Ventures and included participation from new investors Longwood Fund, Asahi Kasei Pharma Ventures, and Alexandria Real Estate Equities, as well as existing Series A investors. The proceeds will support the continued clinical advancement of Mediar's portfolio of anti-fibrotic therapeutics, including therapies targeting systemic sclerosis, idiopathic pulmonary fibrosis, and fibrosis associated with chronic kidney disease. As a part of the transaction, Dr Allan Marchington, Head of ICG Life Sciences, will join Mediar’s board of directors.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ICG plc published the original content used to generate this news brief on January 07, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2601808953?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-07 20:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601808953","market":"fut","top_or_hot":-1,"title":"ICG Leads $76 Million Series B Investment in Mediar Therapeutics","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ICG Leads $76 Million Series B Investment in Mediar <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        ICG plc, through its Life Sciences team, has co-led an oversubscribed $76 million Series B equity financing round for Mediar Therapeutics, Inc., a clinical-stage biotechnology company focused on first-in-class therapies for fibrotic diseases. The round was co-led with Amplitude Ventures and included participation from new investors Longwood Fund, Asahi Kasei Pharma Ventures, and Alexandria Real Estate Equities, as well as existing Series A investors. The proceeds will support the continued clinical advancement of Mediar's portfolio of anti-fibrotic therapeutics, including therapies targeting systemic sclerosis, idiopathic pulmonary fibrosis, and fibrosis associated with chronic kidney disease. As a part of the transaction, Dr Allan Marchington, Head of ICG Life Sciences, will join Mediar’s board of directors.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ICG plc published the original content used to generate this news brief on January 07, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ICG Leads $76 Million Series B Investment in Mediar Therapeutics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nICG Leads $76 Million Series B Investment in Mediar Therapeutics\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-07 20:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ICG Leads $76 Million Series B Investment in Mediar <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        ICG plc, through its Life Sciences team, has co-led an oversubscribed $76 million Series B equity financing round for Mediar Therapeutics, Inc., a clinical-stage biotechnology company focused on first-in-class therapies for fibrotic diseases. The round was co-led with Amplitude Ventures and included participation from new investors Longwood Fund, Asahi Kasei Pharma Ventures, and Alexandria Real Estate Equities, as well as existing Series A investors. The proceeds will support the continued clinical advancement of Mediar's portfolio of anti-fibrotic therapeutics, including therapies targeting systemic sclerosis, idiopathic pulmonary fibrosis, and fibrosis associated with chronic kidney disease. As a part of the transaction, Dr Allan Marchington, Head of ICG Life Sciences, will join Mediar’s board of directors.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ICG plc published the original content used to generate this news brief on January 07, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4194","symbol_name":"办公房地产投资信托","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDL6TjJvQ:1","article_id":"2601808953","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601808953","pubTimestamp":1767789387,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"ICG plc, through its Life Sciences team, has co-led an oversubscribed $76 million Series B equity financing round for Mediar Therapeutics, Inc., a clinical-stage biotechnology company focused on first-in-class therapies for fibrotic diseases. The round was co-led with Amplitude Ventures and included participation from new investors Longwood Fund, Asahi Kasei Pharma Ventures, and Alexandria Real Estate Equities, as well as existing Series A investors. The proceeds will support the continued clinical advancement of Mediar's portfolio of anti-fibrotic therapeutics, including therapies targeting systemic sclerosis, idiopathic pulmonary fibrosis, and fibrosis associated with chronic kidney disease. As a part of the transaction, Dr Allan Marchington, Head of ICG Life Sciences, will join Mediar’s board of directors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-gen","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4194":"办公房地产投资信托","BK4585":"ETF&股票定投概念","ARE":"亚历山大房地产","BK4588":"碎股","BK4225":"医疗保健房地产信托","BK4223":"办公室房地产信托"},"translate_title":"ICG领投Mediar Therapeutics 7600万美元B轮投资","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARE":0.9},"content_text":"ICG Leads $76 Million Series B Investment in Mediar Therapeutics\n\n\n        ICG plc, through its Life Sciences team, has co-led an oversubscribed $76 million Series B equity financing round for Mediar Therapeutics, Inc., a clinical-stage biotechnology company focused on first-in-class therapies for fibrotic diseases. The round was co-led with Amplitude Ventures and included participation from new investors Longwood Fund, Asahi Kasei Pharma Ventures, and Alexandria Real Estate Equities, as well as existing Series A investors. The proceeds will support the continued clinical advancement of Mediar's portfolio of anti-fibrotic therapeutics, including therapies targeting systemic sclerosis, idiopathic pulmonary fibrosis, and fibrosis associated with chronic kidney disease. As a part of the transaction, Dr Allan Marchington, Head of ICG Life Sciences, will join Mediar’s board of directors.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ICG plc published the original content used to generate this news brief on January 07, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2601808953","isCrawlerRequest":true}